We examined the function of two key DNA methyltransferase (DNMT) enzymes in epigenetic regulation of Xlinked cancer/germline (CG-X) antigen genes in human cancer cells, using MAGE-A1, NY-ESO-1, and XAGE-1 as models. In HCT116 cells, genetic knockout of DNMT1 caused moderate activation of CG-X genes, DNMT3b knockout had a negligible effect, and double knockout of both enzymes caused robust gene induction. Similarly, dual DNMT knockout caused dramatic hypomethylation of the MAGE-A1 and NY-ESO-1 promoters, DNMT1 knockout showed moderate hypomethylation, and DNMT3b knockout elicited only slight methylation changes. In contrast, both single and double knockout cells showed significant hypomethylation of the XAGE-1 promoter. RNA interference (RNAi) targeting of DNMT1 in HCT116 cells validated the results seen using genetic knockout cells; however, RNAi targeting of DNMT1 in a different colorectal cancer cell line revealed a greater independent role for DNMT1 in mediating CG-X gene repression and promoter methylation in other cell types. Notably, the histone H3 modification pattern at CG-X promoters was altered following DNMT knockout. DNMT1 or DNMT3b knockout reduced dimethylated lysine-9 (diMe-H3K9) levels, but did not significantly affect dimethylated lysine-4 (diMe-H3K4) or acetylated lysine-9 (Ac-H3-K9) levels. In contrast, dual DNMT1/3b knockout reduced the level of diMe-H3K9 and dramatically increased the levels of diMe-H3K4 and Ac-H3K9 at CG-X gene loci. In summary, DNMT1 and DNMT3b were found to perform both redundant and independent functions in epigenetic regulation of CG-X antigen genes in human cancer cells.
Introduction
Cancer germline (CG) antigens (also known as cancertestis antigens) are a key class of tumor-associated antigens normally expressed only in trophoblast tissue and germline cells; however, these genes are aberrantly expressed in a number of human cancers (Chomez et al., 2001; Koslowski et al., 2004; Simpson et al., 2005) . CG antigen genes have been divided into those residing on the X chromosome (CG-X antigens) or not (non-X CG antigens) (Simpson et al., 2005) . To date, the CG-X antigens have been more widely studied, including the initially described gene MAGE-A1 (van der Bruggen et al., 1991) . The regulatory basis for the selective expression of CG-X antigens in specific tissues appears to be DNA methylation (De Smet et al., 1999) . The first evidence of a role for DNA methylation in the regulation of CG-X antigen expression was provided by experiments using the DNA methyltransferase inhibitor 5-aza-2 0 -deoxycytidine (DAC) (Weber et al., 1994) . Subsequently, the expression of several CG-X antigen genes was shown to inversely correlate with promoter methylation, and to be responsive to activation by DNA methyltransferase inhibitors (De Smet et al., 1996 Weiser et al., 2001; Sigalotti et al., 2002; Karpf et al., 2004) . CG-X gene expression has also been postulated, based on data in human melanoma cell lines, to be associated with global genomic DNA hypomethylation (De Smet et al., 1996) . Although it is clear that promoter DNA methylation is a key regulator of CG-X antigen expression, much less is known about the function of specific DNA methyltransferase (DNMT) enzymes in regulating CG-X antigen expression and promoter methylation. Furthermore, the role of specific histone code modifications in directing CG-X antigen expression, or the relationship of these modifications to DNA methylation status, is unknown.
DNA methyltransferase 1 (DNMT1), the first mammalian cytosine methyltransferase identified, maintains cellular methylation patterns at the DNA replication fork (Bestor, 2000; Robertson, 2001) . In contrast, DNMT3a and DNMT3b are considered de novo methyltransferases because they lack substrate preference for hemimethylated DNA (Okano et al., 1999; Bestor, 2000; Robertson, 2001) . DNMTs mediate transcriptional repression by catalysing DNA methylation and recruiting transcriptional repressor complexes to promoter regions (Bird and Wolffe, 1999; Jones and Baylin, 2002; Karpf and Jones, 2002) . Recent studies using tumor suppressor genes have provided information concerning the role that specific DNMTs play in mediating gene repression and promoter methylation in human cancer cells (Rhee et al., 2000 (Rhee et al., , 2002 Leu et al., 2003; Robert et al., 2003; Ting et al., 2004) . Some of these studies suggest a critical independent role for DNMT1 (Robert et al., 2003) , whereas others implicate cooperativity between DNMT1 and DNMT3b in mediating tumor suppressor gene repression (Rhee et al., 2000 (Rhee et al., , 2002 Ting et al., 2004) .
CG-X antigen genes are qualitatively distinct from tumor suppressor genes in that they are not expressed in non-neoplastic somatic tissues, and their CpG island promoters are methylated in somatic tissues (De Smet et al., 1999) . Two previous studies reported data relevant to understanding the contribution of individual DNMT enzymes to CG-X antigen gene repression (Tao et al., 2002; Koslowski et al., 2004) . Robertson and coworkers observed that the CG-X antigen gene LAGE-1 is silent in cell lines derived from ICF (immunodeficiency, centromere, facial anomalies) syndrome patients (Tao et al., 2002) . Because ICF cells express a catalytically inactive DNMT3b enzyme, this result suggests that DNMT3b does not independently mediate CG-X antigen gene repression. Later, Tureci and co-workers reported that the expression of various CG antigen genes is activated in DNMT1À/À, 3bÀ/À HCT116 human colon cancer cells (Koslowski et al., 2004) . However, this study did not examine whether these changes are related to altered CG gene promoter methylation or histone code modifications, and did not use quantitative methods for gene expression analysis (Koslowski et al., 2004) .
We recently identified CG-X antigen gene activation as a robust and conserved response to DAC treatment in human cancer cell lines, which was absent from normal epithelial cells (Karpf et al., 2004) . These data prompted us to investigate the epigenetic mechanisms involved in regulating CG-X antigen gene expression. We have focused our investigations on three CG-X antigen genes identified in our microarray screen (MAGE-A1, NY-ESO-1, and XAGE-1); these genes represent three distinct CG-X gene families (Simpson et al., 2005) and MAGE-A1 and NY-ESO-1 encode medically relevant antigens under active investigation as cancer immunotherapy targets (Gillespie and Coleman, 1999; Odunsi et al., 2003; Reynolds et al., 2003; Qian et al., 2004; Sigalotti et al., 2004) . These genes each contain 5 0 CpG island promoters that encompass their known transcriptional start sites (Figure 1 ). We examined a number of key epigenetic parameters, including mRNA expression, promoter DNA methylation, and promoter histone code patterns, using an HCT116 model system in which one or both DNMT genes are disrupted by homologous recombination (Rhee et al., 2000 (Rhee et al., , 2002 . Additionally, we examined CG-X antigen expression and promoter methylation in HCT116 and RKO colon cancer cells following specific targeting of DNMT1 by RNA interference (RNAi). Our data reveal that, depending on the target gene and cellular context, DNMT1 and DNMT3b can function either cooperatively or independently to epigenetically regulate CG-X antigen genes.
Results

Activation of CG-X antigen gene expression by DAC treatment
To examine the nature of epigenetic regulation of CG-X antigen genes, we initially pursued a pharmacological approach. Consistent with our previous microarray study (Karpf et al., 2004) , we observed that treatment with DAC, a classical DNMT inhibitor (Christman, 2002) , elicited robust dose-dependent induction of CG-X antigen genes in the colorectal cancer cell lines HCT116 and RKO (Supplemental Figure 1a-c) . Based on previous reports (Cameron et al., 1999; Weiser et al., 2001) , we investigated whether treatment with the histone deacetylase (HDAC) inhibitor Trichostatin A (TSA) enhances the ability of DAC to activate CG-X antigen gene expression. TSA treatment slightly augmented DAC-mediated induction of CG-X antigen expression (Supplemental Figure 1a-c) , as did TSA treatment alone, in both cell types (Supplemental Figure 1b and activation of CG-X antigen gene expression is associated with promoter methylation changes, we examined CG-X antigen gene promoter methylation before and after DAC treatment using methylation-specific PCR (MSP) (Herman et al., 1996) . We observed that all three CG-X promoters are heavily methylated in HCT116 and RKO cells before DAC treatment, and become hypomethylated following treatment (Supplemental Figure 1d) . This result is consistent with the model that DAC-mediated CG-X antigen gene activation is a consequence of promoter DNA hypomethylation. Taken together, these data suggest that DNMTs play a major role in CG-X antigen gene repression, whereas HDACs play a relatively minor accessory role.
Activation of CG-X gene expression by genetic knockout of DNMT1 and DNMT3b Based on the findings presented above, we sought to test the role that specific DNMTs play in epigenetically regulating CG-X gene expression in human cancer cells. For this task, we utilized a genetic DNMT knockout HCT116 model system (Rhee et al., 2000 (Rhee et al., , 2002 . We initially confirmed the genotype and phenotype of the DNMT knockout lines by measuring DNMT1 and DNMT3b expression by Western blot and reverse transcriptase-polymerase chain reaction (RT-PCR), respectively (Supplemental Figure 2a and b) , and by analysing global genomic DNA methylation levels using Liquid chromatography-mass spectrometry (LC-MS) (Song et al., 2005) (Supplemental Figure 2c) . The LC-MS assay revealed that genomic 5mdC levels are moderately depressed (B20%) in DNMT1À/À cells, slightly reduced in DNMT3bÀ/À cells (B2%), and greatly reduced (B70%) in double knockout cells (DKO) (Supplemental Figure 2c) , indicating that the two enzymes cooperate to maintain genomic DNA methylation (Rhee et al., 2002) . Maintenance of the DKO cell line in culture for an additional 17 passages resulted in a slight elevation (B4%) of 5mdC levels (Supplemental Figure 2c) .
We next measured the impact of DNMT1 and DNMT3b loss on CG-X antigen gene expression. End point PCR demonstrated robust expression of all three CG-X genes in DKO cells, but not in DNMT1À/À or DNMT3bÀ/À cells (Figure 2a) . Quantitative real-time PCR (qRT-PCR) confirmed these data, but also revealed a lower, but significant, level of CG-X gene induction in DNMT1À/À cells, with only a very slight effect in DNMT3bÀ/À cells (Figure 2b) . Notably, CG-X antigen gene expression was maintained at similarly high levels in early-and late-passage DKO cells, which distinguishes CG-X genes from the tumor suppressor gene CDKN2A (p16), which is re-silenced by passage 22 in the DKO cell line (Bachman et al., 2003) . Overall, these results demonstrate a partially independent role for DNMT1 in CG-X antigen gene repression and, more generally, reveal a striking functional redundancy between DNMT1 and DNMT3b in mediating CG-X gene repression.
The roles of DNMT1 and DNMT3b in maintaining methylation at CG-X antigen promoters The data presented above indicate that DNMT1 and DNMT3b cooperate to repress CG-X antigen gene expression in HCT116 cells. To determine if this activity reflects the function of these enzymes for maintaining promoter DNA methylation at CG-X gene promoters, we initially studied CG-X promoter methylation in DNMT knockout cells using MSP. These experiments revealed that CG-X gene promoters are predominantly hypermethylated in wild-type HCT116, DNMT1À/À, and DNMT3bÀ/À cells, but are predominantly hypomethylated in DKO cells ( Figure 3a) . Next, to more comprehensively and quantitatively determine the effect of DNMT knockout on CG-X antigen promoter methylation, we performed sodium bisulfite genomic DNA sequencing (Frommer et al., 1992; Clark et al., 1994) . In agreement with MSP, bisulfite sequencing indicated that CG-X antigen gene promoters are heavily methylated in wild-type HCT116 cells (Figure 3b-d) . The relative impact of single or double DNMT knockout on MAGE-A1 and NY-ESO-1 promoter methylation was similar, in that DNMT1 loss caused a moderate depression of methylation, DNMT3b loss had a negligible effect, and DKO cells showed dramatic hypomethylation (Figure 3b and c) . In contrast, the XAGE-1 promoter showed high levels of hypomethylation in both DNMT1À/À and DNMT3bÀ/À cells, and in DKO cells, the contribution of the individual knockouts to hypomethylation was subadditive ( Figure 3d ). This result indicates that whereas DNMT1 and DNMT3b cooperatively methylate certain CG-X antigen promoters, they function independently at others.
CG-X antigen gene expression and promoter methylation following RNAi-mediated DNMT1 knockdown
The results presented above, using DNMT knockout cells, suggest functional redundancy for DNMT1 and DNMT3b in mediating CG-X antigen gene repression (for all three genes) and promoter methylation (for two of three genes). However, some reports suggest that DNMT1 knockdown, via antisense RNA or RNAi, is alone sufficient for methylation-silenced gene re-expression and promoter hypomethylation (Robert et al., 2003; Suzuki et al., 2004) . Thus, to further assess the role of DNMT1 in epigenetic regulation of CG-X antigen genes using a different knockdown approach, we performed RNAi-directed knockdown of DNMT1 in HCT116 cells, using stable transfection of an short hairpin RNA (shRNA) specifically targeting DNMT1, and measured expression and methylation of CG-X antigen genes. We utilized this approach, instead of siRNAs, owing to low transient transfection efficiency in this cell type (data not shown). We confirmed the efficiency of DNMT1 knockdown in specific cell clones using both RT-PCR (data not shown) and Western blot analysis ( Figure 4a ). One control shRNA-expressing clone (C2) and two DNMT1 knockdown clones (D16 and D21) were selected for further analysis of CG-X antigen gene expression using quantitative RT-PCR (qRT-PCR). In agreement with our studies using DNMT1À/À HCT116 cells, the two DNMT1 knock- Table 1 . Diagrams of the three promoters examined, and the position of the MSP primers used, are shown in Figure 1 . U and M indicate PCR reactions containing MSP primers specific for unmethylated and methylated DNA templates, respectively. The DNA methylation level of 5 0 promoter CpG islands of (b) MAGE-A1, (c) NY-ESO-1, and (d) XAGE-1, in the indicated cell lines, was measured by sodium bisulfite DNA sequencing as described in Materials and methods. The primers utilized are listed in Supplemental Table 1 and their approximate location is shown in Figure 1 . Bent arrows indicate transcriptional start sites, and numbers indicate the nucleotide position of the termini of the sequenced region, in relation to the transcriptional start site. The nucleotide positions indicated for XAGE-1 are in relation to the XAGE-1b transcriptional start site. A minimum of 10 individual alleles was sequenced for each sample, and the key (bottom) summarizes the sequencing results at each CpG position (ovals). Methylation percentages (%), shown at right, indicate the total proportion of methylated CpG sites in the entire sequenced region, taking into account all sequenced alleles and all CpG sites, for that sample.
down clones showed only a low level of CG-X antigen gene induction (Figure 4b ). In addition, MSP analysis did not reveal significant hypomethylation of CG-X gene promoters in the DNMT1 knockdown cell clones (Figure 4c ), paralleling our findings using DNMT1À/À cells (Figure 3a) .
To extend this study to a different cell type, we conducted DNMT1 knockdown experiments in RKO cells using siRNA. As shown earlier, in RKO cells, CG-X antigen genes are repressed and their promoters are hypermethylated (Supplemental Figure 1) . We confirmed the efficiency of DNMT1 knockdown by siRNA in RKO cells using both RT-PCR (data not shown) and Western blot analysis (Figure 5a) . Notably, as compared to HCT116, DNMT1 knockdown in RKO cells caused much greater induction of CG-X antigen gene expression, and this effect was most prominent for XAGE-1 (Figure 5b) . Additionally, DNMT1 knockdown in RKO cells, in contrast to HCT116, resulted in substantial hypomethylation of CG-X antigen gene promoters, as shown by MSP (Figure 5c ). These data suggest a greater reliance on DNMT1 alone for maintaining CG-X antigen gene repression and promoter methylation in RKO cells, as compared to HCT116.
Histone H3 tail lysine modifications at CG-X antigen gene promoters in DNMT knockout cells The close connection between DNA methylation and histone code modifications (Bird and Wolffe, 1999; Jones and Baylin, 2002) led us to examine the relationship between DNMT1 and DNMT3b function and histone code modifications present at CG-X antigen gene promoters. We utilized chromatin immunoprecipitation-PCR analyses (ChIP-PCR) to determine the levels of three histone H3 tail lysine modifications at CG-X antigen gene promoters: dimethylated lysine 4 (diMe-H3K4), dimethylated lysine 9 (diMe-H3K9), and acetylated lysine 9 (Ac-H3K9). DiMe-H3K4 and Ac-H3K9 are typically associated with transcriptionally active promoters, whereas diMe-H3K9 is associated with repressed promoters (Lachner et al., 2003) . We initially performed end point ChIP-PCR to examine the H3 modification pattern at CG-X antigen gene promoters in normal HCT116 and HCT116 DKO cells, as these two cell types show the most significant difference in CG-X antigen expression levels and promoter methylation patterns (Figures 2 and 3) . We utilized chromatin extracts from passage 16 DKO cells because this allowed time for scale-up of the DKO cell culture to achieve adequate amounts of material to perform ChIP-PCR, and because both earlier and later passage DKO cells showed similar levels of CG-X antigen gene expression and promoter DNA methylation (Figures 2  and 3 ). ChIP-PCR analyses revealed that all three of the chosen H3 modifications are detectable at CG-X antigen gene promoters in HCT116 cells (Figure 6 ). However, in DKO cells, there is a dramatic decrease in the level of diMe-H3K9, and corresponding increases in the level of both diMe-H3K4 and Ac-H3K9 at each CG-X antigen gene promoter (Figure 6 ). The alterations in the level of these three histone H3 modifications in DKO cells are not uniform throughout the genome, because the promoter of glyceraldehyde 3-phosphate dehydrogenase (Gapdh), which is similarly active in HCT116 and DKO cells (Figure 2a) , did not show altered levels of these modifications ( Figure 6 ). Similarly, downstream exons of the AFP and albumin genes, which are localized in inactive regions of euchromatin (Jiang et al., 2004) , showed comparable levels of each of these three modifications in HCT116 and DKO cells (Figure 6) . Therefore, the changes in the levels of these histone H3 modifications at CG-X antigen gene promoters in DKO Next, we determined the histone H3 modification pattern at CG-X antigen promoters using quantitative ChIP-PCR (qChIP-PCR). In addition to wild-type HCT116 and double DNMT knockout cells, we also examined the single DNMT knockout cells. Surprisingly, qChIP-PCR revealed that the level of diMe-H3K9 at CG-X antigen promoters is reduced not only in DKO cells but also, to a variable extent, in both DNMT1À/À and DNMT3bÀ/À knockout cells (Figure 7a ), indicating that reduced levels of diMe-H3K9 at CG-X antigen gene promoters may not be sufficient to activate CG-X antigen gene expression. However, only DKO cells showed increases in diMe-H3K4 and Ac-H3K9, as compared to HCT116 cells (Figure 7b and c) . Thus, increased levels of diMe-H3K4 and Ac-H3K9 at CG-X antigen gene promoters appears to directly correlate with increased expression of CG-X antigen genes in human cancer cells.
Discussion
Previous studies have established DNA methylation as a key regulator of CG-X antigen gene expression (Weber et al., 1994; De Smet et al., 1996 Karpf et al., 2004) . In contrast, little is known about the specific role of DNMT enzymes in epigenetically regulating CG-X antigen genes in human cancer. Herein we address this question using three model CG-X antigen genes: MAGE-A1, NY-ESO-1, and XAGE-1. Our data reveal that (1) in HCT116 cells, genetic knockout of DNMT1 and DNMT3b robustly induces CG-X antigen gene expression, whereas individual DNMT1 or DNMT3b knockout has a modest or negligible effect, respectively; (2) in HCT116 cells, DNMT1 and DNMT3b cooperate to mediate methylation at the MAGE-A1 and NY-ESO-1 promoters, but function independently at the XAGE-1 promoter; (3) DNMT1 plays a stronger independent role in mediating CG-X antigen gene repression and promoter hypermethylation in RKO cells as compared to HCT116 cells; (4) genetic knockout of both DNMT1 and DNMT3b dramatically alters diMe-H3K9, diMe-H3K4, and Ac-H3K9 levels at CG-X gene promoters, wheras single DNMT1 or DNMT3b knockout only alters diMe-H3K9 levels.
Using a microarray approach, we previously found that treatment of human cancer cells with DAC coordinately activates a large group of CG-X antigen genes, and furthermore, that this effect is specific to cancer cell lines (Karpf et al., 2004) . Our data, reported here, indicate that DAC-mediated induction of CG-X antigen genes is closely associated with promoter DNA hypomethylation. This finding suggests that DACmediated activation of CG-X antigen genes is a direct consequence of DNA hypomethylation, and does not result from mechanism-dependent off-target drug effects, including p53 activation (Karpf et al., 2001; Karpf and Jones, 2002) . Additionally, we observed that treatment of cancer cells with the classical HDAC inhibitor TSA has a subtle effect on CG-X antigen expression, either alone or in combination with DAC, suggesting that DNA methylation, and not histone deacetylation, plays the dominant role in limiting CG-X antigen gene expression in human cancer cells. Similar relative roles for DNA methylation and histone deacetylation in epigenetic gene silencing were reported earlier for tumor suppressor genes (Cameron et al., 1999) .
It was recently observed that the expression of specific CG antigen genes is activated in DKO cells (Koslowski Figure 6 Histone H3 modifications at CG-X antigen gene promoters in wild-type HCT116 and DKO cells. Chromatin immunoprecipitation (ChIP) assay was performed as described in Materials and methods, using the primers listed in Supplemental Table 1 . Chromatin extracts were harvested from passage 16 DKO cells. Three histone H3 modifications were analysed: dimethylated lysine 9 (Me-K9), dimethylated lysine 4 (Me-K4), and acetylated lysine 9 (Ac-K9). NEG indicates a no template PCR control. Inp indicates 5% input DNA, a positive amplification control; IgG indicates ChIP performed using an isotypic antibody control. In addition to CG-X antigen promoters, we amplified the Gapdh promoter as a control for constitutively active euchromatin, and downstream exons of the albumin and a-fetoprotein genes as controls for inactive euchromatin (see text). Figure 7 Quantitative analysis of histone H3 modifications at CG-X antigen gene promoters in single and double DNMT knockout HCT116 cell lines. qChIP-PCR analyses were performed as described in Materials and methods, using the primers listed in Supplemental Table 1 . Three histone H3 modifications at the MAGE-A1, NY-ESO-1, and XAGE-1 promoters were analysed: (a) dimethylated lysine 9 (Me-K9), (b) dimethylated lysine 4 (Me-K4), and (c) acetylated lysine 9 (Ac-K9). The mean values from triplicate data points are plotted, along with error bars that indicate þ s.d. In all cases, the amplification values resulting from specifically immunoprecipitated DNA are normalized to 5% input DNA. et al., 2004) . Consistent with these findings, we observed that MAGE-A1, NY-ESO-1, and XAGE-1 are each robustly activated in DKO cells, but not in single DNMT knockout cells. Additionally, using qRT-PCR, we demonstrate that DNMT1À/À cells show low, but significant levels of induction of CG-X antigen genes, whereas DNMT3bÀ/À cells show very little or no CG-X antigen gene expression. This finding illustrates the value of quantitative gene expression analysis and reveals an independent role for DNMT1 in maintaining CG-X antigen gene repression in these cells. In agreement, RNAi experiments targeting DNMT1 in RKO cells demonstrated that this enzyme can play a more prominent independent role in mediating CG-X antigen gene repression in other cancer cell types, an observation that was also recently reported for specific tumor suppressor genes (Ting et al., 2006) . Additional studies are required to determine whether other DNMT enzymes, including DNMT3a, also play a role in mediating CG-X antigen gene repression in human cancer cells.
Ac-K9
Notably, we find that DNMT1 and DNMT3b cooperate to maintain dense CpG methylation at the MAGE-A1 and NY-ESO-1 promoters, which is consistent with synergistic reactivation of these genes in DKO cells. Functional redundancy of DNMT1 and DNMT3b has also been observed in the maintenance of global genomic DNA methylation, and epigenetic repression and methylation of tumor suppressor genes (Rhee et al., 2002) . This cooperativity or redundancy is most easily explained by interchangeability between the two proteins in epigenetic repressor complexes present in human cancer cells. In support of this idea, both DNMT1 and DNMT3b are known to bind various epigenetic repressors, including HDACs, histone methyltransferases, and Polycomb group proteins (Bird and Wolffe, 1999; Fuks et al., 2003; Vire et al., 2006) . Furthermore, both DNMT1 and DNMT3b are often overexpressed in human cancer cells (Robertson et al., 1999) .
Unlike seen with MAGE-A1 and NY-ESO-1, DNMT knockout experiments did not reveal synergistic methylation of the XAGE-1 promoter by DNMT1 and DNMT3b. Rather, both single DNMT knockout cells showed robust hypomethylation at this particular locus. This was somewhat surprising based on the fact that only DKO cells illustrate robust activation of XAGE-1 gene expression. These data imply that direct catalysis of DNA methylation may not be the chief mechanism by which the XAGE-1 promoter is repressed by DNMTs. An alternative explanation could be that both DNMT1 and DNMT3b are required to facilitate the association of significant levels of transcriptional co-repressors, such as those mentioned above, to the XAGE-1 promoter.
The histone modification patterns that coincide with CG-X antigen gene activity status in human cancer cells have not been previously investigated. We used ChIP-PCR to determine the levels of three critical histone H3 modifications (diMe-H3K4, Ac-H3K9, and diMe-H3K9) at CG-X antigen gene promoters. Consistent with studies of other genes, we find that increased levels of diMe-H3K9 at CG-X antigen promoters correlates with a lack of gene expression, whereas an increased abundance of diMe-H3K4 and Ac-H3K9 at these promoters correlates with increased CG-X antigen gene expression. Dual DNMT1/DNMT3b knockout resulted in large increases of diMe-H3K4 and Ac-H3K9 levels at CG-X promoters, which correlated with increased CG-X antigen gene expression in these cells. Interestingly, both single and dual DNMT knockout led to decreases in the level of diMe-H3K9 at CG-X antigen gene promoters. These data suggest that reduction of diMe-H3K9 levels at CG-X antigen gene promoters may be necessary but not sufficient for CG-X antigen gene expression, and also imply that DNMT1 and DNMT3b can independently facilitate H3K9 dimethylation at CG-X antigen gene promoters. It is plausible that the euchromatic histone methyltransferases G9a or GLP catalyse H3K9 methylation at CG-X antigen promoter loci in human cancer cells, because G9aÀ/À and GLPÀ/ À mouse embryonic cells each show enhanced expression of MAGE-A genes (Tachibana et al., 2002 (Tachibana et al., , 2005 . Furthermore, we have recently found that DNMT1 physically interacts with G9a in human cells (unpublished observations), which could provide a mechanism for communication between H3K9 dimethylation, CG-X antigen repression, and CG-X gene promoter DNA methylation.
CG-X antigens are currently under intense investigation as cancer vaccine targets (Gillespie and Coleman, 1999; Simpson et al., 2005) . The medical importance of CG-X antigens is supported by the observation that vaccine-induced CD8 þ T-cell responses to CG-X antigens, but not to melanoma differentiation antigens, correlates with tumor-free and overall survival in melanoma patients (Reynolds et al., 2003) . Treatment with agents that increase the expression of CG-X antigens, including DAC (Karpf et al., 2004; Sigalotti et al., 2004) and zebularine (Cheng et al., 2004) , constitute an intriguing therapeutic approach by which antitumor immunity to CG-X antigen-directed vaccines could be improved (Karpf and Jones, 2002; Maio et al., 2003; Guo et al., 2006) . However, the toxicity and pleiotropic effects associated with nucleoside analog DNMT inhibitors could be a barrier to the successful clinical implementation of this combination strategy (Karpf and Jones, 2002) . Therefore, it is of particular interest to identify less toxic agents capable of inhibiting DNA methylation (Egger et al., 2004; Lyko and Brown, 2005) . Our findings suggest that any such inhibitors may need to effectively target both DNMT1 and DNMT3b in order to achieve a therapeutically beneficial level of CG-X antigen gene expression in a variety of clinical settings.
Materials and methods
Cell culture and drug treatments
Wild-type, DNMT1À/À, DNMT3bÀ/À, and DNMT1/3b double knockout (DKO) HCT116 colorectal cancer cell lines were a generous gift from Dr Bert Vogelstein (Johns Hopkins University School of Medicine), and were cultured as described previously (Song et al., 2005) . The colon adenocar-cinoma cell line RKO was obtained from the ATCC (Rockville, MD, USA), and was cultured as described previously (Karpf et al., 2001) . For drug treatments, HCT116 or RKO cells were treated once with 0.1 or 1.0 mM DAC (Sigma, St Louis, MO, USA) dissolved in phosphate-buffered saline (PBS), and cultured for an additional 3-5 days before harvesting RNA or DNA for analysis. In other experiments, HCT116 or RKO cells were treated with 0.1 or 1.0 mM DAC once, cultured for 48 h, and then treated with 300 nM TSA (Sigma, St Louis, MO, USA) for an additional 24 h; alternatively, cells were treated with 300 nM TSA alone for 24 h.
RNAi knockdown of DNMT1
To knockdown DNMT1 expression in HCT116 cells using RNAi, stable selection of an shRNA was required because of very low transient transfection efficiency in this cell type (data not shown). A CENIX-pre-designed DNMT1 short hairpin (sh) DNA oligo (sense: 5 0 -GCTTTGTATGTTGGCCAAATT-3 0 , antisense: 5 0 -TTTGGCCAACATACAAAGCTT-3 0 , Ambion Inc, Austin, TX, USA) was cloned into the pSilencer 4.1 CMV puro vector (Ambion Inc, Austin, TX, USA). The DNMT1 sh plasmid or the pSilencer 4.1 CMV puro negative control sh vector (Ambion Inc, Austin, TX, USA) were transfected into HCT116 cells using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA), according to the manufacturer's instructions. Antibiotic selection was performed using 1.5 mg/ml puromycin and was continued until all mocktransfected control cells were killed. shDNMT1 and control sh clones were picked and expanded while maintaining them in normal media supplemented with 0.75 mg/ml puromycin. DNMT1 knockdown was assessed by RT-PCR and Western blotting.
To accomplish DNMT1 knockdown by RNAi in RKO cells, cells were transfected every other day with 5 or 50 nM of wildtype or mismatch DNMT1-specific siRNA oligonucleotides using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA), according to the instructions of the manufacturer. RNA, protein, and DNA extracts were harvested after 5 days of treatment for assessment of DNMT1 knockdown, CG-X antigen gene expression, and CG-X gene promoter methylation. The siRNA duplex used to target DNMT1 corresponded to nucleotide position 436 in the DNMT1 open reading frame and the mutant DNMT1 siRNA oligo was designed to contain three mismatches with the target sequence (indicated by underlining). The siRNA sequences utilized were as follows: DNMT1 siRNA: antisense, 5 0 -AUUACGUAAAGAAGAAU UATT-3 0 , sense, 5-UAAUUCUUCUUUACGUAAUTT-3 0 ; DNMT1 mismatch siRNA: antisense, 5 0 -AUUACUUAAAA AAGAACUATT-3 0 , sense, 5 0 -UAGUUCUUUUUUAAGUA AUTT-3 0 . siRNA oligonucleotides were synthesized at the University of Utah School of Medicine DNA/Peptide synthesis facility.
RT-PCR and qRT-PCR Total RNA was purified using Trizol (Invitrogen, Carlsbad, CA, USA) and the cDNA First Strand Synthesis Kit (Fermentas, Hanover, MD, USA) was used to produce cDNA. Primer sequences, annealing temperatures, and product sizes are reported in Supplemental Table 1 . Primers for MAGE-A1 (Genbank ID 32879920) and NY-ESO-1 (Genbank ID 3255990) were designed using Primer 3 (Rozen and Skaletsky, 2000) , whereas the primers for XAGE-1 (Genbank ID 9885324) were reported previously (Koslowski et al., 2004) . Gradient PCR reactions (iCycler, Bio-Rad Laboratories, Hercules, CA, USA) were used to optimize annealing temperatures for each primer set. Gapdh was amplified as a positive control to confirm equivalent cDNA input. PCR cycle number was empirically determined to be in the linear range of amplification, which was typically 25 cycles for Gapdh, and 30-35 cycles for CG-X antigen genes and DNMT3b. PCR products were fractionated on 1.5% agarose gels and visualized by staining with 250 ng/ml ethidium bromide. Gel images were documented using the BioRad EX gel documentation system (BioRad Laboratories, Hercules, CA, USA).
For qRT-PCR, cDNA samples and standards were analysed using a 7300 Real-Time PCR System (Applied Biosciences, Foster City, CA, USA) and PCR Master Mix for SYBR Green assays (Eurogentech, Seraing, Belgium). Primers were identical to the ones used in standard RT-PCR (Supplemental Table 1 ). Gel-purified PCR product amplification standards for each gene were generated from DKO p.8 cell cDNA via end point RT-PCR, using the appropriate primer pair. For CG-X antigen genes, the following cycling parameters were used: 951C for 10 min, 35 cycles of 951C for 15 s, 601C for 1 min, and 801C for 1 min. Gapdh amplifications utilized 951C for 10 min, 30 cycles of 951C for 15 s, 581C for 1 min, and 771C for 1 min. In all experiments, dissociation curves were performed to confirm specific product amplification. All samples were run in triplicate, and all CG-X antigen gene expression data were normalized to Gapdh.
Western blot analyses
Whole-cell extracts were harvested using RIPA buffer as described previously (Karpf et al., 2001) ; alternatively, nuclear proteins were extracted using the NE-PER kit (Pierce Biochemical, Rockland, IL, USA). Protein concentrations were determined using the Lowry High system (BioRad, Hercules, CA, USA). Equal amounts of protein were fractionated on 4-12% gradient sodium dodecyl sulfatepolyacrylamide gel electrophoresis gels (Invitrogen, Carlsbad, CA, USA). Membranes were blocked with 5% nonfat dry milk in 1 Â Tris-buffered saline (0.1% Tween 20 in 1 Â PBS) for 30 min at room temperature before overnight incubation with primary antibodies. DNMT1 was detected using the polyclonal primary antibody NB100-264 (Novus, Littleton, CO, USA) at a 1:2500 dilution and anti-rabbit IgG (Amersham Biosciences, Piscataway, NJ, USA) at a 1:10 000 dilution. Lamin B was detected using the sc-6217 antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA) and a-Tubulin was detected using the B-5-1-2 antibody (Accurate Chemical and Scientific Corporation, Westbury, NY, USA), along with appropriate secondary antibodies. Western Lightning Chemiluminescence Reagent (PerkinElmer Life Sciences, Boston, MA, USA) was used for protein detection.
Global genomic DNA methylation analyses Genomic DNA samples were isolated using the Puregene kit (Gentra Systems, Minneapolis, MN, USA) as described previously (Song et al., 2005) . Genomic DNA methylation was assessed by direct measurement of the level of 5-methyl-2 0 -deoxycytidine (5mdC) using liquid chromatography-electrospray ionization mass spectrometry (LC-ESI-MS/MS), as described previously (Song et al., 2005) . Briefly, 1 mg genomic DNA samples were enzymatically hydrolysed with Nuclease P1 or Nuclease S1 into component nucleosides, and loaded, along with standards, onto an LC-ESI/MS/MS system. All samples were analysed in triplicate.
CG-X antigen gene promoter DNA methylation analyses MSP (Herman et al., 1996) and sodium bisulfite DNA sequencing (Clark et al., 1994) were used to determine the methylation status of the 5 0 CpG island regions of MAGE-A1, NY-ESO-1, and XAGE-1. The promoter and 5 0 end of each gene was analysed using Webgene (http://www.itb.cnr.it/sun/ webgene//) to locate the position of 5 0 CpG islands (GardinerGarden and Frommer, 1987) . The CpG islands and the location of the primers utilized for DNA methylation analyses are shown in Figure 1 . MSP and sodium bisulfite sequencing primers were designed using MethPrimer (Li and Dahiya, 2002) , and the sequences and annealing temperatures of the primers are reported in Supplemental Table 1 . The approximate position of these primers is shown in Figure 1 . Genomic DNAs were isolated as described above, and sodium bisulfite conversion was performed as described previously (Frommer et al., 1992) . Gradient PCR reactions were used to optimize the annealing temperatures for each primer set. MSP products were fractionated, stained, and visualized in 2.0% agarose gels. Sodium bisulfite DNA sequencing was accomplished by direct cloning of PCR products into the pCR4-TOPO vector (Invitrogen, Carlsbad, CA, USA). A minimum of 10 individual clones from each bisulfite PCR reaction were sequenced at the Roswell Park Cancer Institute Biopolymer core facility, using an ABI prism automated DNA sequencer (Applied Biosystems, Foster City, CA, USA). DNA sequence information was analysed using the Lasergene program (DNA Star, Madison, WI, USA).
ChIP-PCR and quantitative ChIP-PCR analyses (qChIP-PCR)
ChIP-PCR was used to determine the level of specific histone H3 lysine tail modifications at CG-X antigen gene promoters. The modifications measured were lysine 4 dimethylation (diMe-H3K4), lysine 9 acetylation (Ac-H3K9), and lysine 9 dimethylation (diMe-H3K9). ChIP-grade antibodies specific for these modifications were obtained from Upstate Biotechnology (Waltham, MA, USA). Normal rabbit immunoglobulin G (Santa Cruz Biotechnology, Santa Cruz, CA, USA) was utilized as a negative control. DNA sonication conditions were optimized to produce B500 bp DNA fragments using a Branson Sonifier 150 (VWR International, Bridgeport, NJ, USA) and are available upon request. ChIP-PCR primers were designed using Primer 3 (Rozen and Skaletsky, 2000) and are reported in Supplemental Table 1 . PCR cycle number was empirically determined to be in the linear range of amplification. ChIP-PCR products were visualized by ethidium bromide staining in 2.0% agarose gels. For qChIP-PCR, DNA samples and standards were analysed using a 7300 Real-Time PCR System (Applied Biosciences, Foster City, CA, USA) and PCR Master Mix for SYBR Green assays (Eurogentec, Seraing, Belgium). Primers were identical to the ones used in ChIP-PCR (Supplemental Table 1 ). Gel-purified PCR product amplification standards for each gene were generated via end point PCR of input DNA from HCT116 cells, using the appropriate primer pair. In all experiments, the following cycling parameters were used: 501C for 2 min, 951C for 10 min, 40 cycles of 951C for 15 s, 61-621C for 30 s, and 81-841C for 1 min. Dissociation curves were performed to confirm specific product amplification. All samples were run in triplicate, and all qChIP-PCR data were normalized to 5% input DNA amplifications. Numerous attempts to analyse the NY-ESO-1 promoter by real-time PCR failed, so for this promoter locus, we performed qChIP-PCR by densitometry scanning (Quantity One 1-D Analysis, BioRad, Hercules, CA, USA) of linear range PCR products in ethidium bromide-stained 2.0% agarose gels. For this analysis, all samples were run in triplicate, and all data were normalized to amplification products from 5% input DNA.
